1Geisel School of Medicine, Dartmouth College, Hanover, New Hampshire. 2Thayer School of Engineering, Dartmouth College, Hanover, New Hampshire.

A novel topical formulation of a BRAF inhibitor significantly reduced acneiform rash associated with anti–epidermal growth factor receptor (EGFR) therapies in patients with colorectal cancer ...

One of the consequences of developing acneiform rash is treatment discontinuation or delay of EGFR-targeted therapies. In this study, Patel and her team found that treatment interruptions of anti ...

AstraZeneca, a global biopharmaceutical company is in collaboration with Revna Biosciences (www.RevnaBio.com), a precision medicine research and advanced diagnostics company to provide EGFR (Epidermal ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

A total of 337 treatment-naïve patients with EGFR-sensitive mutation-positive locally advanced or metastatic NSCLC were enrolled and randomized 1:1 to receive either limertinib or gefitinib. The ...

During a live event, Xiuning Le, MD, PhD, discussed updated intracranial efficacy, overall survival, and safety of amivantamab plus lazertinib in patients with EGFR-mutated non–small cell lung cancer.

Department of Respiratory and Critical Care Medicine, The Affiliated Hospital of Qingdao University, Qingdao, China The most common epidermal growth factor receptor (EGFR) mutation in non-small cell ...